These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35166948)

  • 21. Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.
    Pei Y; Li Y; Liang Y; Xu L; Huang X; Li Y; Tang W; Jiang X
    Int J Clin Pharm; 2020 Dec; 42(6):1440-1446. PubMed ID: 32974856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.
    Annemans L; Moeremans K; Lamotte M; Garcia Conde J; van den Berg H; Myint H; Pieters R; Uyttebroeck A
    Support Care Cancer; 2003 Apr; 11(4):249-57. PubMed ID: 12673464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clarifying the role of rasburicase in tumor lysis syndrome.
    Sood AR; Burry LD; Cheng DK
    Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of the Administration Period of Rasburicase in Japanese Adult Hematological Malignancy Patients at High-Risk for Tumor Lysis Syndrome].
    Kobayashi S; Yasu T; Sato K; Ohno N; Kuroda S
    Gan To Kagaku Ryoho; 2018 May; 45(5):879-881. PubMed ID: 30026457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute tumor lysis syndrome in solid tumors--a case report and review of the literature.
    Baeksgaard L; Sørensen JB
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):187-92. PubMed ID: 12655435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concurrent acute spontaneous tumor lysis syndrome complicated with multiple organ failure in a patient with pre-existing undiagnosed lung cancer.
    Amiri FS
    CEN Case Rep; 2015 Nov; 4(2):233-237. PubMed ID: 28509107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series.
    Latha SM; Krishnaprasadh D; Murugapriya P; Scott JX
    Indian J Nephrol; 2015; 25(2):91-4. PubMed ID: 25838646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
    Gupta G; Seth T; Garg V; Juneja R; Mahapatra M; Datta SK; Upadhyay AD; Saxena R
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e99-e104. PubMed ID: 33039358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification.
    Khalighi PR; Martens KL; White AA; Li S; Silgard E; Frieze D; Garcia DA; Li A
    J Oncol Pharm Pract; 2020 Apr; 26(3):529-535. PubMed ID: 31167612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.
    Galardy PJ; Hochberg J; Perkins SL; Harrison L; Goldman S; Cairo MS
    Br J Haematol; 2013 Nov; 163(3):365-72. PubMed ID: 24032600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome.
    Philips A; Radhakrishnan V; Ganesan P; Ganesan TS; Ramamurthy J; Dhanushkodi M; Sagar TG
    Indian J Hematol Blood Transfus; 2018 Oct; 34(4):618-622. PubMed ID: 30369730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase.
    Usami E; Kimura M; Iwai M; Teramachi H; Yoshimura T
    Mol Clin Oncol; 2017 Jun; 6(6):955-959. PubMed ID: 28588796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
    Kennedy LD; Ajiboye VO
    J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey.
    Bertrand Y; Mechinaud F; Brethon B; Mialou V; Auvrignon A; Nelken B; Notz-Carrère A; Plantaz D; Patte C; Urbieta M; Baruchel A; Leverger G;
    J Pediatr Hematol Oncol; 2008 Apr; 30(4):267-71. PubMed ID: 18391694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
    Vines AN; Shanholtz CB; Thompson JL
    Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia.
    Martens KL; Khalighi PR; Li S; White AA; Silgard E; Frieze D; Estey E; Garcia DA; Hingorani S; Li A
    Leuk Res; 2020 Feb; 89():106298. PubMed ID: 31945598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
    McDonnell AM; Lenz KL; Frei-Lahr DA; Hayslip J; Hall PD
    Pharmacotherapy; 2006 Jun; 26(6):806-12. PubMed ID: 16716134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
    Knoebel RW; Lo M; Crank CW
    J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intricate Interplay of Entwined Metabolic and Inflammatory Life-threatening Processes in Tumor Lysis Syndrome Complicating Prostate Cancer: A Systematic Review with a Single Institution Experience.
    Findakly D; Wang J
    Cureus; 2020 Mar; 12(3):e7395. PubMed ID: 32226700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spontaneous Tumor Lysis Syndrome: A Case Report and Critical Evaluation of Current Diagnostic Criteria and Optimal Treatment Regimens.
    Weeks AC; Kimple ME
    J Investig Med High Impact Case Rep; 2015; 3(3):2324709615603199. PubMed ID: 26904699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.